Key Points
- Dyne Therapeutics director Brian Posner bought 2,500 shares at an average price of $17.12, a transaction worth $42,800 that increased his ownership by 16.13% to 18,000 shares.
- The company recently reported a smaller-than-expected quarterly loss of $0.73 per share, beating analysts’ estimate of a $0.77 loss, though full-year earnings are still projected to remain negative.
- Wall Street sentiment is mixed but generally constructive, with a Moderate Buy consensus rating and an average target price of $35.00, above the stock’s recent trading level around $17.37.
Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Brian Posner bought 2,500 shares of the firm's stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average price of $17.12 per share, with a total value of $42,800.00. Following the purchase, the director owned 18,000 shares in the company, valued at $308,160. This trade represents a 16.13% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Dyne Therapeutics Price Performance
Shares of NASDAQ:DYN opened at $17.37 on Friday. The business has a 50 day moving average price of $18.28 and a 200 day moving average price of $18.39. Dyne Therapeutics, Inc. has a twelve month low of $8.06 and a twelve month high of $25.00. The company has a market cap of $2.87 billion, a price-to-earnings ratio of -5.39 and a beta of 1.08. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period in the prior year, the company posted ($1.05) EPS. Research analysts predict that Dyne Therapeutics, Inc. will post -2.99 earnings per share for the current year.
Institutional Trading of Dyne Therapeutics
A number of hedge funds have recently modified their holdings of DYN. AQR Capital Management LLC bought a new stake in shares of Dyne Therapeutics in the 1st quarter worth approximately $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Dyne Therapeutics by 5.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company's stock worth $597,000 after acquiring an additional 2,886 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Dyne Therapeutics by 58.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company's stock worth $10,407,000 after acquiring an additional 366,183 shares during the period. Caxton Associates LLP bought a new stake in shares of Dyne Therapeutics in the 1st quarter worth approximately $157,000. Finally, Creative Planning lifted its position in shares of Dyne Therapeutics by 23.8% in the 2nd quarter. Creative Planning now owns 14,541 shares of the company's stock worth $138,000 after acquiring an additional 2,797 shares during the period. Institutional investors own 96.68% of the company's stock.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on DYN shares. Chardan Capital restated a "buy" rating and set a $38.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 9th. Sanford C. Bernstein increased their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the company a "market perform" rating in a research note on Wednesday, May 13th. Weiss Ratings restated a "sell (d-)" rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Wall Street Zen upgraded Dyne Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, May 16th. Finally, Evercore set a $33.00 target price on Dyne Therapeutics in a research note on Friday, May 15th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $35.00.
Read Our Latest Stock Analysis on DYN
Dyne Therapeutics Company Profile
(
Get Free Report)
Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.
Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
